Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in EuropeFirst published 25/06/2024 Last updated 23/05/2025 EU PAS number: EUPAS49233StudyOngoing